A phase 1 NEJM interim analysis found that a single infusion of the investigational base-editing therapy VERVE-102 produced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results